Shirley Chen
Stock Analyst at Barclays
(3.10)
# 4,657
Out of 12,268 analysts
37
Total ratings
59.3%
Success rate
6.9%
Average return
Main Sectors:
Stocks Rated by Shirley Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | $22 | $24.00 | -8.33% | 5 | May 7, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Buy | $350 → $470 | $447.20 | +5.10% | 5 | Feb 24, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | $105 | $77.46 | +35.55% | 1 | Dec 15, 2025 | |
| SWX: NOVN Novartis AG | Maintained: Sell | $90 | $119.46 | -24.66% | 6 | Nov 21, 2025 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | $1,875 → $2,000 | $1,723.63 | +16.03% | 9 | Nov 10, 2025 | |
| LON: GSK GSK plc | Maintained: Hold | $15 | $1,915.00 | -99.24% | 6 | Oct 31, 2025 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | $140 | $13,916.00 | -98.99% | 5 | Oct 21, 2025 |
Lakefront Biotherapeutics NV
May 7, 2026
Maintained: Sell
Price Target: $22
Current: $24.00
Upside: -8.33%
Swedish Orphan Biovitrum AB (publ)
Feb 24, 2026
Maintained: Buy
Price Target: $350 → $470
Current: $447.20
Upside: +5.10%
Sanofi
Dec 15, 2025
Maintained: Buy
Price Target: $105
Current: $77.46
Upside: +35.55%
Novartis AG
Nov 21, 2025
Maintained: Sell
Price Target: $90
Current: $119.46
Upside: -24.66%
Genmab A/S
Nov 10, 2025
Maintained: Buy
Price Target: $1,875 → $2,000
Current: $1,723.63
Upside: +16.03%
GSK plc
Oct 31, 2025
Maintained: Hold
Price Target: $15
Current: $1,915.00
Upside: -99.24%
AstraZeneca PLC
Oct 21, 2025
Maintained: Buy
Price Target: $140
Current: $13,916.00
Upside: -98.99%